Icon

BOSULIF (nda203341)- (EQ 100MG BASE,EQ 500MG BASE,EQ 400MG BASE)

BOSUTINIB MONOHYDRATE PF PRISM CV
EQ 100MG BASE,EQ 500MG BASE,EQ 400MG BASE
Yes No
2034-Aug-28 2017-Sep-04
2019-Sep-04 None
None No
BOSULIF is a kinase inhibitor indicated for the treatment of adult patients with  Newly-diagnosed chronic phase Ph+ chronic myelogenous leukemia (CML).  Chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy.
0 2 0
Total Other Developers 6
Drugs with Suitability No
EQ 100MG BASE ** ** - - -
EQ 500MG BASE ** ** - - -
EQ 400MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.